 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Key Insights Institutions' substantial holdings in Celcuity implies that they have significant influence over the...

Celcuity Inc.'s (NASDAQ:CELC) large institutional owners must be happy as stock continues to impress, up 12% over the past week

Celcuity (NASDAQ:CELC - Free Report) had its price target hoisted by Needham  Company LLC from $23.00 to $24.00 in a research report released on Thursday, Benzinga reports. Needham  Company...

Celcuity (NASDAQ:CELC) Price Target Increased to $24.00 by Analysts at Needham & Company LLC

Celcuity (NASDAQ:CELC - Get Free Report) had its price objective increased by equities researchers at Needham & Company LLC from $23.00 to $24.00 in a research report issued to clients and investors...

Celcuity (NASDAQ:CELC  Free Report) had its target price lifted by Craig Hallum from $20.00 to $25.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has a buy...

Celcuity (NASDAQ:CELC) Given New $25.00 Price Target at Craig Hallum

Celcuity Inc. (CELC) has disclosed a new risk, in the Share Price & Shareholder Rights category. Celcuity Inc. faces significant financial risks as...

Celcuity Inc.'s Balancing Act: Navigating Financial Risks in Capital Raising Endeavors

This is a signal that CELC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Celcuity (CELC, $21.58) RSI Indicator left the overbought zone on March 28, 2024

This is a Bullish indicator signaling CELC's price could rise from here. Traders may explore going long the stock or buying call options...

Celcuity (CELC, $21.58) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 28, 2024

This price move could be a signal that CELC may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Celcuity (CELC, $21.58) price may drop as it broke higher Bollinger Band on Mar 28, 2024

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC Research Report) and Erasca (ERAS...

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Volume (M)	200,027.00
52-Wk High	$22.19
52-Wk Low	$8.39

CELC Celcuity Inc

About

Feed

News

Sentiment

Earnings

Fundamentals